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ABSTRACT 27 
Background: Age-related muscle loss (sarcopenia) may be driven by a diminished 28 
myofibrillar protein synthesis (MyoPS) response to anabolic stimuli (i.e. exercise and 29 
nutrition). Oral phosphatidic acid (PA) ingestion has been reported to stimulate resting 30 
muscle protein synthesis in rodents, and enhance resistance training-induced muscle 31 
remodelling in young humans. Purpose: This study examined the effects of acute oral PA 32 
ingestion on resting and exercise-induced MyoPS rates in older individuals. Methods: 33 
Sixteen older males performed a bout of unilateral leg resistance exercise followed by oral 34 
ingestion of 750mg of soy-derived PA or a rice-flour placebo (PL) over 60 min post-exercise. 35 
A primed-continuous infusion of L-[ring-13C6]-phenylalanine with serial muscle biopsies was 36 
used to determine MyoPS at rest and between 0-150 and 150-300 min post-exercise. Results: 37 
Plasma [PA] concentrations were elevated above basal values from 180-300 min post-38 
exercise in PA only (P = 0.02). Exercise increased MyoPS rates above basal values between 39 
150-300 min post-exercise in PL (P = 0.001), but not PA (P = 0.83). Phosphorylation of 40 
p70S6K, rpS6, 4E-BP1 and Akt was elevated above basal levels in the exercised leg over 41 
150-300 min post-exercise for PL only (P = 0.018, 0.007, 0.011 and 0.002, respectively), and 42 
were significantly greater than PA (P < 0.01 for all proteins). The effects of oral PA ingestion 43 
on proteolytic signaling markers was equivocal. Conclusions: Acute oral phosphatidic acid 44 
ingestion appears to interfere with resistance exercise-induced intramuscular anabolic 45 
signaling and MyoPS in older males and, therefore, may not be a viable treatment to 46 
counteract sarcopenia. Clinicaltials.gov registration no: NCT03446924 47 
 48 
Word count: 250 (excluding sub-headings) 49 
 50 
 51 
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INTRODUCTION 52 
Age-related loss of skeletal muscle mass and strength, also termed sarcopenia [1], is 53 
associated with premature mortality [2] and leads to myriad adverse health consequences 54 
such as impaired functional capacity [3], increased risk of fractures [4], and metabolic disease 55 
[5]. Whilst the incidence of age-related muscle wasting has been observed in people as young 56 
as 45 y, its prevalence increases with advancing age [6]. The healthcare costs associated with 57 
sarcopenia are extensive and, in the context of a rapidly expanding global ageing population, 58 
are expected to increase considerably in the coming decades [7].   59 
Skeletal muscle proteostasis is dependent on the equilibrium between muscle protein 60 
synthesis (MPS) and muscle protein breakdown (MPB). One of the most effective strategies 61 
to attenuate the progression of sarcopenia is resistance exercise (RE) training [8-10]. In 62 
young individuals, RE robustly increases MPS by 2 to 3-fold [11], thereby enhancing overall 63 
net protein balance for muscle hypertrophy [12, 13]. However, the acute MPS response to RE 64 
is blunted in older compared with younger individuals [14, 15], which may explain the 65 
impaired muscle remodelling response to prolonged training in older age [15, 16]. The age-66 
related blunting of the muscle anabolic response to RE may be underpinned by impairments 67 
in ribosomal biogenesis and/or translational efficiency in the mechanistic target of rapamycin 68 
complex 1 (mTORC1) signaling pathway [14, 15, 17]. Collectively, these data have 69 
galvanized the search for strategies to abolish the impaired muscle anabolic response to RE 70 
and maximize the therapeutic benefits of this non-pharmacological intervention in the old. 71 
The lipid second messenger phosphatidic acid (PA) has been touted as an important 72 
factor in the regulation and activation of mTORC1 for MPS. Specifically, mechanical 73 
contraction increases the activity of diacylglycerol kinase ζ to convert diacylglycerol into PA, 74 
which in turn, binds mTORC1 directly at the FKB12 rapamycin binding (FRB) domain [18, 75 
19], increasing its activity and ultimately enhancing protein translational efficiency [20]. 76 
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Exogenous PA administration in cell culture is converted to lysophosphatidic acid [21], 77 
thereby inactivating the tuberous sclerosis complex (TSC1/2) through the extracellular 78 
regulated kinase (ERK) pathway to bolster mTORC1-mediated signaling [22]. 79 
Mechanistically, acute oral PA ingestion was reported to stimulate mTORC1-mediated 80 
signaling with a tendency to increase MPS in rodents [23]. Given that mechanical load-81 
induced PA and exogenous PA appear to converge on mTORC1 through distinct proximal 82 
pathways, exogenous PA provision (via oral ingestion) may modulate the anabolic response 83 
to RE in older individuals [24]. Indeed, studies in healthy young humans report that orally 84 
ingested PA enhances strength and lean body mass gains when consumed daily during 85 
prolonged RE training [25, 26]. However, there is a need for further in vivo human 86 
investigation of the bioavailability and intramuscular mechanisms through which this 87 
purported ‘nutraceutical’ compound acts before introduction to the older population [27]. 88 
Therefore, the primary aim of the present study was to establish the effects of acute 89 
oral PA ingestion on rates of myofibrillar protein synthesis (MyoPS) and intramuscular 90 
signaling at rest and in response to a bout of RE in older individuals. We hypothesised that 91 
PA ingestion alone would not stimulate MyoPS, but would modulate RE-induced 92 
intramuscular signaling and MyoPS rates in older individuals compared with a placebo.  93 
 94 
METHODS 95 
Participants 96 
Sixteen older males were recruited for the present study (age 68.9 ± 2.8yrs, range 65-75yrs). 97 
All participants were recreationally active and deemed healthy based on their responses to a 98 
general health questionnaire. Participants suffering from uncontrolled hypertension or 99 
generalised neuromuscular, metabolic or cardiovascular diseases were excluded from the 100 
study. Furthermore, taking part in regular structured resistance exercise whilst partaking in 101 
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the current study, smoking, and consuming non-steroidal anti-inflammatory drugs or any 102 
medication that might interfere with muscle metabolism, rendered the participant ineligible to 103 
participate. Prior to obtaining written consent, participants were informed of the purpose and 104 
methodology of the study. Ethical approval was obtained through the Solihull Research 105 
Ethics Committee (15/WM/0228). The study conformed to the latest guidelines set by the 106 
Declaration of Helsinki (7th edition). This trial is registered at Clinicaltials.gov registration 107 
no: NCT03446924 108 
 109 
Experimental design 110 
Following an initial screening, participants visited the laboratories of the School of Sport, 111 
Exercise and Rehabilitation Sciences (SportExR) on two separate occasions. The study was 112 
parallel-designed and single-blinded, with participants randomized to receive either the 113 
placebo control (PL; n = 8) or phosphatidic acid treatment (PA, n = 8). During the initial 114 
visit, anthropometric characteristics and isotonic leg strength were determined. 115 
Approximately one week after this initial visit, participants underwent an experimental trial 116 
to determine the muscle anabolic properties of supplemental PA. The experimental trial 117 
consisted of a stable isotope amino acid infusion combined with serial muscle biopsies to 118 
determine the MyoPS response to PA or PL consumption alone, or in combination with 119 
resistance exercise.  120 
 121 
Preliminary Assessments 122 
Body mass and height: Participant body mass was recorded in loose clothing and without 123 
shoes to the nearest 0.1kg using a digital balance scale. Height was determined to the nearest 124 
0.1cm using a stadiometer. 125 
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Body composition: Following determination of body mass and height, participants underwent 126 
a dual energy x-ray absorptiometry scan (DXA) (Discovery DXA Systems, Hologic Inc., 127 
Bedford, MA) to determine whole-body and regional bone mineral density, fat- and fat-free 128 
mass. DXA scans were performed after a ~10 h overnight fast. Participants rested supine on 129 
the scanner in loose clothing with their feet positioned at shoulder width apart and held in 130 
place with micropore tape. Each scan took 7 min and was analysed by a trained DXA 131 
operator.  132 
Isotonic leg strength: Participant knee extensor one repetition maximum (1 M) strength was 133 
estimated in the dominant leg using a leg extension machine (Cybex VR-3, Medway, MA, 134 
USA) in order to determine the appropriate load of 75% 1RM for the subsequent 135 
experimental trial. Briefly, prior to exercise commencement, a baseline blood pressure 136 
measurement was obtained to ensure participants were normotensive (diastolic blood 137 
pressure 60-90 mmHg, systolic blood pressure 120-140 mmHg) to reduce the risk of adverse 138 
events during heavy-load, fatiguing RE. Following blood pressure assessment, participants 139 
initiated a self-selected 1-set warm-up after which the exercising load was gradually 140 
increased over subsequent sets until participants were unable to perform >10 repetitions. This 141 
final load was used to estimate knee extensor 1RM strength via the Brzycki equation [28]. 142 
The increment in loading was based on subjective ratings of exercise intensity, which were 143 
recorded immediately after each lifting attempt using a modified Borg category-ratio scale 144 
(CR-10) [29]. Each exercise set was separated by 2 min of passive rest. Strength assessments 145 
were led by a trained strength and conditioning specialist. 146 
Dietary and activity control: Participants were asked to fast 10 hours overnight for both the 147 
initial and experimental trial visit, but were provided with a standardised meal on the evening 148 
prior to the experimental trial only. The meal contained ~787 kcal, comprised of ~19% 149 
protein (~37.5 g), ~46% carbohydrate (~90.7 g) and 35% fat (30.8 g). Participants were asked 150 
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to abstain from alcohol and caffeine for 24 h prior to the experimental trial. Furthermore, 151 
participants were asked to refrain from strenuous exercise for 48 h prior to the experimental 152 
trial. 153 
 154 
Experimental Trial 155 
Following a 10-hour overnight fast, participants returned to the SportExR laboratory at 0630 156 
h following a ~10 h overnight fast. Upon arrival, a 21G cannula was inserted in an 157 
antecubital vein of both forearms. One cannula was used for frequent blood sampling, whilst 158 
the other was used to administer a stable isotope amino acid infusion. After obtaining a 159 
baseline blood sample, a primed continuous infusion of L-[ring-13C6] phenylalanine was 160 
initiated (prime: 2 µmol⋅kg-1; infusion: 0.05 µmol⋅kg-1, Cambridge Isotope Laboratories, 161 
Andover, MA, USA). The contralateral arm was warmed to ~60°C using an electric heating 162 
blanket to obtain arterialized blood samples at -180, -120, -60 and immediately prior to 163 
exercise, and at 20, 40, 60, 90 ,120, 180, 240 and 300 min of post-exercise recovery. A total 164 
of 10 mL of arterialized blood was sampled at each time point and separated into 165 
ethylenediaminetetraacetic (EDTA) and serum separator vacutainers (BD, Oxford, UK). 166 
Blood samples were centrifuged for 10 min at 3000G and 4°C. Plasma and serum were 167 
aliquoted and stored at -80°C until further analyses. After ~150 min of stable isotope 168 
infusion, a muscle biopsy was obtained under local anaesthesia (1% lidocaine) from the 169 
quadriceps vastus lateralis of the non-dominant, non-exercised leg using the Bergström 170 
technique [30]. Muscle biopsy tissue was quickly rinsed in ice-cold saline and freed from any 171 
visible blood, connective tissue and fat before being snap-frozen in liquid nitrogen and stored 172 
at -80°C.  Immediately after biopsy obtainment, participants completed a unilateral leg 173 
extension RE bout of the dominant leg to elicit a rise, but not maximise, MyoPS [31]. 174 
Resistance exercise consisted of two warm-up sets of 12 repetitions at 50% of their 175 
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previously estimated 1RM followed by 6 sets of 12 repetitions at 75% of their estimated 176 
1RM, to elicit a rating of ~8-9 on the Borg CR-10 scale. Exercise sets were interspersed by 2 177 
min of passive rest during which participants remained seated on the machine. Participants 178 
completed the exercise with a lifting-lowering cadence of ~1 sec without pause. Time-under-179 
tension and Borg CR-10 rating were recorded after each exercise set. Following RE 180 
completion, participants consumed their respective PA or placebo control treatment over 1 h 181 
post-RE (described in detail below) and remained in a supine position for the remainder of 182 
the experimental trial. At 150 and 300 mins after starting treatment consumption, muscle 183 
biopsies were obtained from the non-exercised and exercised legs. Muscle biopsies were 184 
sampled ~2-3 cm from one another in a distal-to-proximal orientation. An overview of the 185 
experimental trial is provided in Figure 1. 186 
 187 
Treatment Administration 188 
Immediately and 60 min after RE completion, participants consumed two gelatine capsules 189 
(i.e. 4 capsules in total), each containing 375 mg of either a rice-flour placebo control (PL) or 190 
phosphatidic acid-enriched soybean phospholipid supplement (PA; Mediator® 50P, 191 
ChemiNutra, Austin, US). Treatment capsules were visually identical and ingested with 192 
water. The phospholipid composition of PA was; 50-60% phosphatidic acid, 5-15% 193 
phosphatidylcholine, 5-15% phosphatidylethanolamine, 1-5% phosphatidylinositol, 1-5% 194 
lyso-phosphatidylcholine, 1-5% N-acyl phosphatidyl ethanolamine. Thus, the total 1500mg 195 
of ingested supplement material provided ~750mg of PA over 1 h post-exercise. Supplements 196 
were ingested post-RE completion to minimize any potential negative effects of RE on gut 197 
absorption kinetics and minimize splanchnic extraction of PA [32] (i.e. absorption by 198 
intestinal mucosa). Based on the data of Purpura et al. [33] and our own pilot work in 199 
younger males, PA was ingested in a biphasic manner to ensure plasma PA concentrations 200 
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remained elevated for the majority of the RE recovery period. The PA supplement source and 201 
total ingested dose was similar to that used by others demonstrating; i) robust increases in 202 
p70S6K signaling in cultured cells [25], ii) elevated rates of MPS and mTORC1-mediated 203 
signaling in rats when consumed acutely in a similar equivalent dose for humans [23], iii) an 204 
increase in circulating PA and lysophosphatidic acid concentrations in a young male [33] and 205 
iv) augmented lean body mass and strength increases when consumed during prolonged 206 
resistance training in young males [25, 26], albeit using a different ingestion pattern to that 207 
chosen here. 208 
 209 
Blood Analyses 210 
Plasma amino acids, isotope enrichment and serum insulin 211 
Plasma [13C6] phenylalanine enrichment was determined by gas chromatography-mass 212 
spectrometry (GCMS; model 5973; Hewlett Packard, Palo Alto, CA, USA) by monitoring 213 
ions 234/240. Briefly, 300 µL of plasma was diluted 1:1 with acetic acid before being 214 
purified through cation-exchange columns and dried down overnight under nitrogen. The 215 
purified amino acids were then converted to their N-tert-butyldimethyl-silyl-N-216 
methyltrifluoracetamide (MTBSTFA) derivative. Simultaneously, leucine and phenylalanine 217 
concentrations were measured by GCMS using the internal standard method based on the 218 
known volume of plasma and internal standard added and the known amino acid 219 
concentration of the internal standard. The internal standards were U-[13C6] leucine (ions 220 
302/308) and U-[13C9–15N] phenylalanine (ions 336/346) added in a ratio of 100 µL⋅ml−1 of 221 
blood. Insulin concentrations were measured using commercially available enzyme-linked 222 
immunosorbent assay kit (IBL International, Hamburg, Germany). 223 
 224 
Plasma phosphatidic acid concentration 225 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 10
Plasma [PA] was determined in a subset of participants (PA: n = 4; PL: n = 4) using the 226 
internal standard method, where 0.0013 mg of C17:0 PA (Avanti Polar Lipids, #830856) was 227 
added to 500 mL of plasma. Plasma lipids were extracted according to Folch et al [34] using 228 
a chloroform, methanol and acidified salt solution (2:1:0.8 v/v). Once extracted, lipids were 229 
re-dissolved in chloroform:methanol (2:1 v/v) before being spotted onto an HPTLC silica 230 
plate and separated into its component lipid fractions using a chloroform, petroleum ether, 231 
methanol, acetic acid and boric acid solvent mix (40:30:20:10:1:8 v/v). The PA position was 232 
identified using a TLC identification standard (Larodan AB, #37-0140 Phosphatidic Acid 233 
(egg PC)) before being removed and esterified, worked up and separated into fatty acids by 234 
gas chromatography (Agilent 7890 Gas Chromatograph with FID Detector, Agilent UK) 235 
using a carbowax column (Agilent, CP-Wax52CB). Plasma [PA] concentrations are 236 
expressed as µg/mg plasma and fold-change from basal values, due to inherent background 237 
variability in [PA] between participants. 238 
 239 
Muscle Tissue Analyses 240 
Myofibrillar protein enrichment 241 
The myofibrillar protein fraction and muscle free pool were extracted for the analysis of 13C6 242 
phenylalanine enrichment from ~30 mg of muscle tissue as previously described [35]. 243 
Briefly, muscle tissue samples were homogenised in a 2 mL microtube using clean sharp 244 
scissors. Homogenised samples were placed on a shaker (IKA, Vibrax, Germany) for 10 min 245 
at room temperature at 1500 rpm and subsequently centrifuged at 11000 g for 15 min at 4°C. 246 
The supernatant containing the amino acid free pool (IC) was transferred to a clean microtube 247 
and the myofibrillar pellet washed twice through centrifugation at 11000 g for 15 min at 4°C 248 
with 500 µL homogenisation buffer. To separate the collagen fraction from the myofibrillar 249 
pellet, the pellet was incubated in 750 µL of 0.3 M NaOH for 30 min at 30°C, giving the 250 
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sample a vortex mix at 15 and 30 min. The sample was then spun at 13000 rpm for 10 min at 251 
4°C and the supernatant transferred to a 4 mL glass collection tube. A 750 µL volume of 0.3 252 
M NaOH was then added to the pellet, centrifuged at 13000 rpm for 10 min at 4°C and the 253 
supernatants combined. Myofibrillar proteins were then precipitated by adding 1 mL of 1 M 254 
PCA, which was centrifuged at 3200 rpm for 20 min at 4°C. The pellet was washed twice 255 
with 2 mL of 70% ethanol. The remaining myofibrillar pellet was hydrolysed at 110°C 256 
overnight in 1 mL of 0.05 M HCl and 1 mL of activated Dowex 50W-X8 100-200 resin (Bio-257 
Rad laboratories INC, USA). Constituent amino acids of the myofibrillar fraction were 258 
purified on cation-exchange columns by eluting with 2 M NH4OH and evaporating to 259 
dryness. Amino acids were then derivatised as their n-acetyl-n-propylester, and phenylalanine 260 
labelling determined by gas chromatography-combustion-isotope mass spectrometry (Delta 261 
Plus XP, Thermofisher Scientific, Hemel Hempstead, UK).  262 
 263 
Intramuscular signaling 264 
Western blot analyses were performed on the sarcoplasmic protein fraction obtained during 265 
myofibrillar protein isolation (described above). Ubiquitin protein conjugates were analysed 266 
using separate sarcoplasmic protein fractions with the addition of 2-chloroacetamide (Sigma-267 
Aldrich, St. Louis, MO) to a final concentration of 100 mM. Sarcoplasmic protein content 268 
was determined by a DC protein assay before western blot aliquots of 2 µg protein per 1 µL 269 
were prepared in 4x Laemmli sample buffer and sucrose lysis buffer and subsequently boiled 270 
for 5 min. Equal amounts of protein (30 µg) were loaded onto 7.5–15 % gels and separated 271 
by SDS-PAGE for 1 h. Following electrophoresis, proteins were transferred onto a biotrace 272 
nitrocellulose membrane (Pall Laboratory, Portsmouth, U.K.) for 1 h at 100 V, or in regard to 273 
the ubiquitinated proteins, S6 ribosomal protein (rps6), (LC3 a/b) and Caspase-3 onto a 274 
polyvinylidene fluoride (PVDF) membrane for 2.5h at 60 V. Membranes were subsequently 275 
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blocked in 5 % milk for 1 h and washed 3 times for 5 min in TBST before being incubated 276 
overnight at 4°C in following primary antibodies: Muscle Ring Finger protein 1 (MuRF1: 277 
Santa Cruz Biotechnology, Dallas, Texas, U.S; sc-398608), mono- and polyubiquitinylated 278 
conjugates (FK2: Enzo Life Sciences LTD, Exeter, U.K.) phospho-p70S6K1 Thr389 (#9205), 279 
total 70 kDa S6 protein kinase (p70S6K1; #9202), phospho-eukaryotic initiation factor 4E 280 
binding protein (4E-BP1) Thr37/46 (#9459), total 4E-BP1 (#9452), phospho-eukaryotic 281 
elongation factor 2 (eEF2) Thr56 (#2331), total eEF2 (#2332), phospho-protein kinase B 282 
(Akt) Ser473 (#3787), total Akt (#9272), phospho-AMP activated protein kinase α (AMPKα) 283 
Thr172 (#2535), total AMPKα (#5831), phospho-p44/42 MAPK (Erk 1/2)Thr202/Tyr204 284 
(#4370), total p44/42 MAPK (#4695), phospho-rps6 Ser240/244, total rps6 (#2217), LC3a/b 285 
(#12741) and Caspase-3 (#9665) each purchased from Cell Signaling Technology (New 286 
England Biolabs (UK) Ltd, Hitchin, U.K.). Membranes were then washed 3 times for 5 min 287 
in TBST and incubated for 1 h in their respective secondary antibody and washed again 3 288 
times for 5 min in TBST. Protein quantification was achieved by incubating the membranes 289 
for 5 min in Immobilon Western chemiluminescent HRP substrate (Merck Millipore, 290 
Watford, UK) before being imaged using a G:BOX Chemi XT4 imager using GeneSys 291 
capture software (Syngene, Cambridge, U.K.). Bands were quantified using Image Studio 292 
Lite (Li-Cor, Lincoln, Nebraska, U.S.). 293 
 294 
Calculations 295 
MyoPS rates were calculated from 13C6 phenylalanine incorporation by using the standard 296 
precursor-product model: 297 
FSR (%⋅h-1) = ∆ Eb / Ep x 1 / t x 100  298 
Where ∆ Eb is the difference in bound 13C6 phenylalanine enrichment between two biopsy 299 
samples, Ep is the mean plasma precursor enrichment and t is the time in min between muscle 300 
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biopsy samples. Basal MyoPS rates were calculated in the rested/fasted state using the pre-301 
infusion plasma 13C6 phenylalanine enrichment as a proxy for basal muscle protein 302 
enrichment, a technique that has previously been previously validated in tracer naïve older 303 
individuals [36]. 304 
 305 
Statistics 306 
Data analysis was performed using SPSS version 22 (IBM, Chicago, IL, USA). 307 
Anthropometric and exercise parameters were analysed using a one-way ANOVA. MyoPS 308 
rates, intracellular signaling, plasma PA concentrations and insulin were analysed using a 309 
two-way, repeated measures ANOVA with one within (three levels; basal, early and late 310 
MyoPS) and one between factor (two levels; group). A Tukey’s HSD post hoc test was 311 
performed whenever a significant F ratio was found to determine specific differences. 312 
Significance was set at p < 0.05 for all analyses. All values are presented as means ± SD or 313 
SEM. 314 
 315 
RESULTS 316 
Anthropometric and Exercise Variables 317 
There were no significant differences between PA and PL for anthropometric or strength 318 
characteristics (Table 1). Similarly, RE variables including knee extension 1RM (P = 0.43), 319 
total time-under-tension (P = 0.61), time-under-tension per set (P = 0.43), total volume (P = 320 
0.46), volume per set (P = 0.46) and average load per set (P = 0.43) were not significantly 321 
different between PLA and PA (Table 1). 322 
 323 
Plasma Amino Acid, Phosphatidic Acid and Serum Insulin Concentrations 324 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 14
Plasma leucine and phenylalanine concentrations did not change from basal values during the 325 
experimental trial and were similar between groups at all time-points (Figure 2A and B, 326 
respectively). Serum insulin concentration decreased significantly below basal values by 90 327 
min post-exercise cessation until 240 and 300 min post-exercise in PL (P < 0.05) and PA (P < 328 
0.05), respectively, with no differences between groups (Figure 2C). Plasma 13C6 329 
phenylalanine enrichment significantly increased above basal values (-180 min) 60 min after 330 
initiation of the stable isotope tracer infusion and remained elevated for the duration of the 331 
trial in PL and PA (P < 0.001). Linear regression analysis revealed that the 13C6 332 
phenylalanine enrichment slopes in both groups were not significantly different from zero, 333 
confirming the obtainment of an isotopic steady state (Figure 2D). Plasma PA concentration 334 
was significantly elevated above basal values at 180 min post-exercise (P = 0.02) until 300 335 
min post-exercise (P = 0.01) in PA only. There was no difference from basal plasma [PA] 336 
values in PL (Figure 3A and B). Fold-change in plasma [PA] concentration was significantly 337 
greater in PA compared with PL at 240 and 300 min post-exercise (P = 0.026 and 0.020, 338 
respectively).  339 
 340 
Myofibrillar Protein Synthesis 341 
Basal-state, temporal MyoPS rates (0-150 min and 150-300 min) and aggregate MyoPS rates 342 
(0-300 min) in rested and exercised legs are presented in Figure 4A and 4B. MyoPS rates in 343 
the rested leg did not differ from basal values at any time-point, nor between groups. In the 344 
exercised leg, MyoPS rates over 150-300 min were significantly greater than basal values (P 345 
= 0.001) and 0-150 min (P = 0.019) in PL only, and were ∼40% greater than basal values 346 
over the aggregate 0-300 min in PL only (P = 0.023). In the exercised leg, there was a strong 347 
trend for greater MyoPS rates over 150-300 min in PL compared with PA (P = 0.051). 348 
Temporal and aggregate MyoPS rates did not differ from basal values in rested or exercised 349 
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legs in PA, although there was a tendency for a reduction in MyoPS from basal values in the 350 
rested leg over 150-300 min in PA only (P = 0.053).  351 
 352 
Intramuscular Signaling 353 
Anabolic Signaling 354 
Phosphorylation of p70S6KThr389, 4EBP1Thr37/46, AktSer473 and rps6Ser240/244 in the PL exercised 355 
leg were, respectively, elevated 3.6-, 1.7-, 2.4- and 2.2-fold compared with baseline values at 356 
150 min (P = 0.002; P = 0.019, P < 0.001 and P = 0.021 respectively), and remained 357 
significantly elevated 300 min post RE (P = 0.003; P = 0.001, P = 0.025 and P = 0.007 358 
respectively). In the PL rested leg, AMPKαThr172 phosphorylation at 300 min was, 359 
respectively, 1.7- and 1.9-fold greater than corresponding values at baseline (P = 0.028) and 360 
150 min (P = 0.002). At 150 min, p70S6KThr389, AktSer473 and rps6Ser240/244 phosphorylation in 361 
the PL exercised leg were greater than corresponding resting values at 150 min (P = 0.002, P 362 
= 0.002 and P = 0.004 respectively). At 300 min, 4EBP1Thr37/46, p70S6KThr389 and AktSer473 363 
phosphorylation in the PL exercised leg were elevated compared with the corresponding 364 
rested leg (P = 0.002, P = 0.001 and P = 0.009 respectively). In the PA group, p70S6KThr389 365 
phosphorylation was significantly elevated from basal values 150 min upon exercise 366 
completion (P = 0.047). Rps6Ser240/244 was 2.1-fold elevated in the PA exercised compared 367 
with the rested leg at 150 min (P = 0.037), whilst AMPKαThr172 was 1.9-fold greater in the 368 
exercised compared with rested leg at 300 min (P = 0.027). Between-group differences were 369 
observed at 150 min in the rested leg for 4E-BP1Thr37/46  (P = 0.022) and in the exercised leg 370 
for AktSer473 (P < 0.001), whilst between-group differences at 300 min were apparent in the 371 
rested leg for AMPKαThr172 (P = 0.001) and in the exercised leg for p70S6KThr389 (P = 0.046), 372 
4EBP1Thr37/46 (P = 0.005) and rps6Ser240/244 (P = 0.003) phosphorylation. No changes were 373 
found for MAPKSer44/42 and eEF2Thr56 phosphorylation (Figure 5A-F).  374 
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 375 
Proteolytic Signaling 376 
MuRF1 protein content (Figure 6A) was elevated 1.2-fold from baseline values in the PA 377 
rested leg at 300 min (P = 0.019), and 1.4-fold in PL exercised leg at 300 min compared with 378 
their corresponding resting value (P = 0.002). Between-group differences for Murf1 protein 379 
content occurred in the rested leg at 300 min (P = 0.019). Total ubiquitinated protein 380 
conjugates (Figure 6B) in the PL rested leg were, respectively, elevated 1.4- and 1.3-fold 381 
above basal values at 150 (P = 0.001) and 300 min (P = 0.005), and were greater than 382 
corresponding exercising values at 150 (P = 0.008)  and 300 min (P =0.007). Between-group 383 
differences were apparent for the resting leg at 150 (P < 0.001) and 300 min (P = 0.002). 384 
Quantification of a single distinct band at ~30 kDa (Figure 6C) revealed significantly 385 
elevated total protein ubiquitination in the PL exercised leg at 150 min compared with basal 386 
values (P = 0.011) and corresponding resting values (P = 0.047; Figure 6B). Ubiquitinated 387 
proteins seemed to occur mainly above 100 kDa. LC3 II protein content (Figure 6D) was 388 
elevated from baseline values 150 min post exercise in PL (P = 0.027). Higher LC3 II protein 389 
contents were found in PL compared with PA at 150 (P < 0.001) and 300 min (P = 0.015) in 390 
the exercising leg, and at 150 min in the resting leg (P = 0.003). Total Caspase-3 (Figure 6E) 391 
protein decreased in the PL resting leg from 150 min to 300 min (P = 0.022). 392 
 393 
DISCUSSION 394 
At the forefront of strategies to combat sarcopenia is the development of novel 395 
interventions to enhance MyoPS and overcome the ‘anabolic resistance’ of aged skeletal 396 
muscle. In this regard, PA has been touted as a nutraceutical with muscle anabolic properties, 397 
phosphorylating mTORC1-mediated signaling leading to enhanced protein translational 398 
efficiency [24, 27]. Both endogenous PA production [37] and exogenous PA provision [22] 399 
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phosphorylate mTORC1 and associated distal signaling proteins (i.e. p70S6K and 4E-BP1) in 400 
cell culture and animal models, albeit via different pathways. Herein, we aimed to investigate 401 
these separate but synergistic effects of distinct PA-mediated signaling pathways on MyoPS 402 
in older individuals through acute oral PA provision alone or combined with mechanical 403 
loading. Following PA ingestion, plasma [PA] concentrations rose above basal values at 180 404 
min post-exercise. Surprisingly, PA ingestion inhibited the RE-induced rise in intramuscular 405 
anabolic signaling and MyoPS observed in PL over 5 h of recovery. No robust group 406 
interactions were found, likely due to the relatively small sample size studied. Thus, our 407 
findings suggest that, in an acute experimental setting, oral PA provision has an interference 408 
effect on the muscle remodelling response to RE in older individuals. 409 
Reconciling the present findings of a potential PA-induced interference effect on 410 
MyoPS is difficult considering the established in vitro evidence that PA exerts anabolic 411 
effects on mTORC1-mediated signaling [22, 25, 38]. Support for our findings can be gleaned 412 
from the work in rodents [23], in which a whey protein-induced rise in MPS was attenuated 413 
by co-ingestion of PA, at a dose equivalent to that provided herein. Despite dampened MPS 414 
rates with PA co-ingestion, mTORC1-mediated signaling events were numerically greater 415 
with combined whey protein plus PA. The authors suggested PA may have altered mTORC1-416 
mediated signaling, causing the peak MPS time to shift. The results of our study support 417 
similar inhibitory effects of PA on MyoPS, particularly in the presence of a second anabolic 418 
stimulus (i.e. RE). In contrast to the work of Mobley et al. [23], our findings demonstrate that 419 
acute oral PA ingestion prevented any RE-induced rise in anabolic signaling, which most 420 
likely impaired protein translational efficiency and prevented a similar MyoPS response to 421 
that observed in PL  [39]. Elucidating the mechanisms underlying the tendency towards 422 
lower resting MyoPS rates over 150-300 min post-PA ingestion is more challenging. These 423 
observations are in stark contrast to Mobley et al. [23], in which PA ingestion alone increased 424 
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anabolic signaling and potentially MPS. These discrepant findings could be attributed to the 425 
different species studied (rodents vs. humans). Besides PA-related alterations in downstream 426 
mTORC1-meditated signaling, acute oral PA supplementation did not alter the ERK 427 
signaling pathway, which has been suggested to be an important mechanistic link between 428 
exogenous PA provision and mTORC1-mediated signaling in vivo [40]. The PA-induced 429 
activation of ERK, and thus mTORC1 signaling, hinges on the conversion of PA to 430 
lysophosphatidic acid (LPA), which, in turn, depends on the presence of the converting 431 
enzyme phospholipase A (PLA) [22]. Thus, the absence of between group differences in 432 
MAPK signaling, in response to exogenous oral PA ingestion, suggests that this route of 433 
administration may not have altered LPA production. Taken together, the present findings 434 
demonstrate an impaired anabolic signaling response to RE when combined with acute PA 435 
ingestion, reinforcing the lack of any MyoPS response. 436 
In addition to MyoPS and anabolic signaling, changes in proteolysis and proteolytic 437 
signaling events may play an important role in the overall net muscle protein balance to RE 438 
[41]. Therefore, we were interested to see if acute oral PA ingestion modulated any potential 439 
change in RE-induced proteolytic signaling. Earlier work conducted by Jaafar et al. [42] 440 
revealed distinctive anti-proteolytic characteristics for PA. Specifically, overexpressing 441 
myotubes with the PA precursor, phospholipase D1, protected against the atrophy-promoting 442 
agent dexamethasone, whilst PA provision protected against the atrophying effects of TNF-α. 443 
In our in vivo human ageing model, we found equivocal effects of oral PA ingestion on 444 
intracellular proteolytic signaling. Whereas Caspase-3 did not reveal any significant between 445 
group differences, 30kDa Ubiquitin-conjugates and LC3-II seemed to be higher in PL 446 
compared with PA. However, it is important to acknowledge that others have previously 447 
observed that alterations in the ubiquitin proteasome pathway are not easily reconciled with 448 
observed effects on muscle protein turnover [43]. Furthermore, the proteolytic markers 449 
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measured in the present study only represent a small fraction of the vast complexity of the 450 
signaling proteins that regulate proteolysis and offer only snapshots of this dynamic 451 
processes. Without direct measurement of myofibrillar breakdown rates, which is technically 452 
challenging, the effects of orally ingested PA on proteolysis remain inconclusive 453 
The specific mechanisms through which PA interferes with RE-induced MyoPS and 454 
potentially impairs basal-state MyoPS in older individuals are intriguing. One possibility is 455 
that PA-derived production of diacylglycerol, catalysed by the enzyme phosphatidic acid 456 
phosphatase, may impair insulin signaling and blunt MyoPS rates [44-46]. Indirect evidence 457 
for lipid-induced impairment in MyoPS is apparent from our recent findings of a negative 458 
association between fat mass and postprandial MyoPS rates in older individuals [47]. 459 
Furthermore, Stephens et al. [48] reported a suppression in postprandial MPS rates and 460 
mTORC1-mediated signaling (i.e. anabolic resistance) when insulin resistance was induced 461 
via lipid infusion in healthy young individuals. It is important to note that Stephens et al. [48] 462 
infused lipid intravenously over 7 h, bypassing splanchnic absorption, resulting in a 463 
circulating lipid milieu that was substantially greater and occurred more rapidly than our 464 
acute oral PA ingestion protocol. Furthermore, intravenous lipid infusion resulted in 465 
significant intramuscular lipid metabolite accumulation, which would directly explain 466 
impairments in insulin signaling and MPS. In the present study, acute oral PA ingestion 467 
significantly increased plasma [PA] ~2-3-fold from 180 min post-ingestion, which coincided 468 
with the temporal impairment in MyoPS over 150-300 min post-exercise. Unfortunately, due 469 
to limitations on biopsy tissue sampling, we can only speculate as to whether the increase in 470 
plasma [PA] following acute oral PA ingestion altered intracellular lipid content and insulin 471 
resistance. What is clear, is that events arising from the extracellular increase in [PA] were 472 
sufficient to impair mTORC1-mediated signaling and MyoPS.  473 
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Although we have provided the first in vivo mechanistic investigation of orally 474 
ingested PA in humans, there is still much to be understood about the muscle anabolic 475 
properties of this purported nutraceutical. Centred around previous animal studies 476 
establishing the muscle anabolic properties of acute PA consumption [23], we chose to 477 
administer a similar equivalent oral dose based on the per species conversion calculations of 478 
Reagan-Shaw et al [49], in an attempt to understand whether these responses would translate 479 
to an in vivo human ageing model. The delayed rise in plasma [PA] following PA ingestion, 480 
compared with case study values reported by others [33], might be due to the biphasic 481 
ingestion protocol, where the second dose of PA was ingested 60 min after the first. 482 
However, we acknowledge that the timing of PA ingestion around RE may influence any 483 
potential anabolic effects of this compound. Indeed, enhancements in RE-induced strength 484 
and lean body mass in young males were reported when supplemental PA was consumed 485 
prior-to (450mg) and immediately after (300mg) RE training [25], although others failed to 486 
replicate these findings [50]. In theory, replicating the PA ingestion pattern of Joy et al. [25] 487 
would have shifted the increase in plasma [PA] above basal values to ~60 min earlier than 488 
observed (i.e. 120 min post-exercise), which, we posit, is unlikely to have significantly 489 
altered MyoPS responses. Nonetheless, given that plasma [PA] concentrations remained 490 
elevated above basal levels at 5 h post-RE, we cannot rule out MyoPS responses >5 h post-491 
RE might have differed between PL and PA. In light of evidence of the importance of 492 
contraction-induced elevations in intracellular [PA] for mTORC1 activation, and the reported 493 
anabolic properties of prolonged PA supplementation [25, 51], our finding of an inhibitory 494 
effect of acute PA ingestion could indicate that longer-term supplementation may be 495 
necessary to increase in intracellular [PA] and muscle anabolism in older individuals. In 496 
support of this notion, supplementation of lipid-based nutritional compounds, omega-3 poly-497 
unsaturated fatty acids and arachidonic acid, over 4-8 weeks has been reported to alter 498 
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intracellular lipid composition and modulate the acute anabolic signaling and ribosome 499 
biogenesis response to RE in young individuals [52, 53]. Thus, an important next step is to 500 
investigate whether longer-term PA supplementation alters intramuscular [PA] and enhances 501 
the acute MyoPS response to RE in older individuals, in addition to better understanding of 502 
how supplemental PA dosing and ingestion pattern can be altered to ‘optimize’ delivery. 503 
In summary, this is the first in vivo study to characterise the effects of acute oral PA 504 
ingestion on MyoPS and intramuscular signaling at rest and post-RE in older individuals. 505 
Oral PA ingestion attenuated the RE-induced increase in MyoPS. The precise cause of the 506 
apparent interference effect of oral PA ingestion on RE-induced muscle anabolism in older 507 
individuals remains to be fully elucidated, but seems to be underpinned by impaired 508 
intramuscular anabolic signaling. Based on our acute mechanistic findings, oral PA ingestion 509 
does not appear to be an effective means of enhancing the muscle anabolic response to RE in 510 
older individuals. However, longer-term supplementation studies are required to fully 511 
understand whether this purported nutraceutical holds any anabolic potential for aged skeletal 512 
muscle. 513 
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TABLES 
 
Table 1. Participant anthropometric, strength and resistance exercise characteristics. 
 PL (n = 8) PA (n = 8) 
Age (yrs) 69.4 ± 3.6 68.4 ± 1.8 
Age range (yrs) 65 – 75 66 – 70 
Body mass (kg) 73.9 ± 7.4 73.7 ± 8.9 
BMI (kg⋅m-2) 23.1 ± 1.6 24.4 ± 2.1 
Whole-body FM (kg) 16.4 ± 2.9 19.4 ± 4.0 
Leg FM (kg) 5.2 ± 1.0 5.9 ± 1.5 
Whole-body FFM (kg) 53.6 ± 5.7 50.6 ± 5.6 
Leg FFM (kg) 17.1 ± 1.4 16.1 ± 1.9 
Knee extension 1RM (kg) 87.4 ± 18.3 79.4 ± 20.7 
Training volume (kg) 1918 ± 377 1725 ± 602 
Volume per set (kg) 320 ± 63 288 ± 100 
Time-under-tension total (sec) 183 ± 37 170 ± 66 
Time-under-tension per set (sec) 31 ± 6 28 ± 11 
Average load per set (kg) 26.9 ± 4.3 24.3 ± 8.2 
Average Borg CR-10 8.4 ± 1.4 8.1 ± 1.5 
 
Values are presented as means ± SD. BMI; body mass index, FM; fat-mass, FFM; fat-free 
mass, 1RM; one-repetition maximum, Borg CR-10; Borg category-ratio scale. 
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FIGURES 
 
Figure 1: Schematic overview of the experimental trial. PA; 750mg of phosphatidic acid-
enriched soybean phospholipid supplement, PL; 750mg of rice-flour placebo. 
 
Figure 2: Plasma phenylalanine (A), leucine (B) and insulin concentration (C) and 13C6 
phenylalanine enrichment (D) in experimental trials. At t = 0 and 60 min, participants orally 
ingested 750mg of PA or PL with water. ∗ indicates significantly different from basal fasting 
values (-180 min) for PL and PA. † indicates significantly different from basal fasting values 
for PA only. Values are means ± SEM. Significance was set at P < 0.05. 
 
Figure 3: Plasma PA concentrations expressed as absolute values (A) and fold-change from 
basal (B). At t = 0 and 60 min, participants orally ingested 750mg of PA or PL with water. 
Subscript a indicates significantly greater than basal values (0 min) for PA. Subscript b 
indicates significantly greater than values at 60 min for PA. * indicates significant between-
group difference at the same time-point. Values are means ± SEM. Significance was set at P 
< 0.05. 
 
Figure 4: Myofibrillar fractional synthesis rate (FSR) during basal postabsorptive conditions 
(prior to exercise and/or treatment administration) and over the 0-150 and 150-300 or 
aggregate 0-300 min post-exercise recovery period in the resting leg (REST; A) and 
exercised leg (EX; B) after oral ingestion of PA or PL. ∗ indicates significantly greater than 
basal state MyoPS rates in the same leg, † indicates significantly greater than MyoPS rates 
over 0-150 min in the same leg. Values are means ± SEM. Significance was set at P < 0.05. 
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Figure 5: Intracellular signaling phosphorylation of p70S6KThr389 (A), 4E-BP1Thr37/46 (B), 
AktSer473 (C), eEF2Thr56 (D), ERK1/2Thr202/Tyr204 (E) and AMPKThr172 (F) expressed as fold-
change from basal values at 150 and 300 min post-exercise in rested and exercised legs with 
PA and PL ingestion. ∗ indicates significantly greater than basal value, ‡ indicates significant 
within-treatment difference from value at 150 min, † indicates significant different from 
rested leg at the same time-point, # indicates significant between-treatment difference at same 
time-point. Values are presented as means ± SEM. Significance was set at P < 0.05. 
 
Figure 6: Intracellular proteolytic markers for the abundance of MuRF1 (A), total ubiquitin 
conjugates (B) ubiquitinated proteins at 30 kDa (C), LC3 (D) and Caspase-3 (E) expressed as 
fold-change from basal, normalized to Ponceau. ∗ indicates significantly greater than basal 
value, † indicates significant different from rested leg at the same time-point, # indicates 
significant between-treatment difference at same time-point. Values are presented as means ± 
SEM. Significance was set at P < 0.05. 
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